Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice

Limitations in efficacy and/or tolerance of currently available urate-lowering therapies (ULTs), such as oral xanthine oxidase inhibitors, uricosurics, and intravenous uricase agents contribute to the development of refractory gout. Renal excretion is the major route of uric acid elimination, but th...

Descripción completa

Detalles Bibliográficos
Autores principales: Pierzynowska, Kateryna, Deshpande, Aditi, Mosiichuk, Nadiia, Terkeltaub, Robert, Szczurek, Paulina, Salido, Eduardo, Pierzynowski, Stefan, Grujic, Danica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732547/
https://www.ncbi.nlm.nih.gov/pubmed/33330529
http://dx.doi.org/10.3389/fmed.2020.569215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732547/
https://www.ncbi.nlm.nih.gov/pubmed/33330529
http://dx.doi.org/10.3389/fmed.2020.569215

Ejemplares similares